Abeona Therapeutics Inc vs VanEck Junior Gold Miners — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while VanEck Junior Gold Miners trades at $119.49. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, VanEck Junior Gold Miners nearer its low. Which is the better fit depends on your goals.
| ABEO | GDXJ | |
|---|---|---|
Market Cap | $421.19M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $7.45 | $156.19 |
52-Week Low | $4.17 | $71.22 |
Enterprise Value | $276.10M | — |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
GDXJ (VanEck Junior Gold Miners ETF) trades at $119.44, up 0.56% with a bullish technical signal from moving averages but bearish oscillators. The ETF shows mixed sentiment with institutional selling by Amundi reducing its stake by 50.5% in the latest quarter (Defense World, August 6, 2026). Recent underperformance versus peers and gold ETFs highlights challenges in the junior gold mining sector.
Outlook remains cautious due to high RSI levels suggesting overbought conditions and sector-specific headwinds. Investment opportunity hinges on gold price momentum, but risks include Federal Reserve policy uncertainty and competitive pressure from senior miners. Analyst sentiment is neutral with concerns about portfolio composition and small-cap exposure.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →